A New Jersey drug maker is recalling 3,744 bottles of a combination blood pressure medication after the tablets failed an FDA dissolution test

The Class II recall covers certain lots of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets expiring May 31, 2027; the FDA says the risk of serious harm is remote.